Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Appoints CEO Michel Spagnol as Chairman

Published: Wednesday, March 05, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
Novasep presents strategic developments.

Novasep has announced the appointment of Michel Spagnol as chairman of the Supervisory Board, following the departure of Roger-Marc Nicoud, the founder of the group. Novasep also provides an update of its strategic projects.

Michel Spagnol joined Novasep as its CEO in June 2013. Since then, he has reinforced the executive management team with the appointments of Christian Thiry as chief financial officer, Thierry Van Nieuwenhove as president of the Synthesis Business Unit and the promotion of Nadege Laborde as president of the Industrial Biotech Unit.

Michel Spagnol also engaged the company in a number of strategic orientations, encompassing commercial, operational, human and innovation excellence, aimed at focusing on customer satisfaction.

Novasep has achieved significant milestones for its key development projects, such as the completion of the world’s largest chromatographic plant for the purification of omega-3s at its Mourenx facility, France, and the successful validation of its ADC payload commercial production workshops at its Le Mans facility, France.

In the last nine months, these facilities and the Leverkusen site in Germany received successful FDA inspections, demonstrating Novasep’s continued commitment to quality.

“Since October 2012, as chairman of Novasep’s Supervisory Board, I have assisted the executive management team in order to ensure that my succession proceeds in the best possible conditions,” said Roger-Marc Nicoud. “Novasep achieved satisfying growth in 2013. The company has promising projects underway and the necessary human and financial resources to achieve them. With the arrival of Michel Spagnol as CEO, I consider my support work to be completed. I have decided to devote myself entirely to other technical and scientific activities. I wish Michel all the best in his new role of CEO and chairman of the Supervisory Board and great success to all Novasep employees.”

“I thank Roger Marc for his never-ending enthusiasm and contribution to the group’s development and I have profound respect for what he has achieved,” said Michel Spagnol, CEO and chairman of the Supervisory Board. “A unique entrepreneur, he succeeded in building from scratch a global leader in the life science manufacturing industry, recognized worldwide for its unique technologies and capabilities. Novasep is evolving, with a strong leadership team and a new logo ‘Passion and smart processes’, representing our refocused strategy. We will continue building on our strong foundations while developing on the excellence of our services and technologies. I wish Roger-Marc continued success in his new endeavors.”

“We would like to thank Roger-Marc who, over the last year and a half, has contributed his unprecedented experience and scientific expertise as chairman of Novasep’s Supervisory Board. We wish him all the best for his new endeavors,” said Jean-Yves Gilet, director - Bpifrance ETI/GE.

Gilet continued, “We are confident about Novasep’s recent developments. The company is implementing promising projects such as the ADC payload production capacities in the Le Mans facility and the chromatographic plant for the purification of omega-3s in Mourenx. We fully support its strong management team led by Michel Spagnol who we are happy to see appointed as chairman of the Supervisory Board.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!